Consider Endari for Patients on Hydroxyurea Who Still Have Sickle Cell Crises
December 2017
Endari (en-DAH-ree, L-glutamine) is the first sickle cell treatment to be approved in almost 20 years.
Endari is for patients 5 years and older to reduce acute sickle cell complications...such as pain crises, acute chest syndrome, etc.
It's thought to work by reducing oxidative damage to "sickled" red blood cells. This may prevent the cells from adhering to blood vessels, causing thrombosis and reducing blood flow.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote